Market Place
Sourcing Support
OKYO Abstract Chosen For Premier Global Ophthalmology Conference
23 Feb 2026 //
GLOBENEWSWIRE
OKYO Pharma Presents Urcosimod Phase 2 Data at ASCRS Meeting
30 Jan 2026 //
GLOBENEWSWIRE
OKYO Pharma Announces Successful Type C Meeting With The FDA
28 Jan 2026 //
GLOBENEWSWIRE
FDA Approves Urcosimod 0.05% to Treat Neuropathic Corneal Pain
23 Jan 2026 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman And Founder Acquires Shares
15 Dec 2025 //
GLOBENEWSWIRE
Okoyo Pharma Reports Positive Corneal Nerve Results
11 Dec 2025 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman And Founder Acquires Shares
21 Nov 2025 //
GLOBENEWSWIRE
OKYO Pharma To Present At OIS XV In San Diego
18 Nov 2025 //
GLOBENEWSWIRE
Okoyo Pharma Initiates 100-Patient Trial For Urcosimod
22 Sep 2025 //
GLOBENEWSWIRE
OKYO Pharma`s Phase 2 Results for Urcosimod in Corneal Pain
16 Jul 2025 //
GLOBENEWSWIRE
FDA Grants OKYO Fast Track for Urcosimod Neuropathic Corneal Pain
01 May 2025 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.